MRA Advisory Group’s Bristol-Myers Squibb BMY Stock Holding History

MRA Advisory Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$352K	Sell	5,646 -18,006	-76%	-$1.14M	0.13%	99
2026 Q2	$1.36M	Buy	+23,652	New	+$1.36M	0.49%	48
2025 Q1	–	Sell	-3,964	Closed	-$224K	–	133
2024 Q4	$224K	Sell	3,964 -621	-14%	-$34.7K	0.12%	95
2024 Q3	$237K	Sell	4,585 -1,303	-22%	-$61.1K	0.13%	88
2024 Q2	$245K	Buy	+5,888	New	+$263K	0.14%	84
2023 Q3	–	Sell	-4,704	Closed	-$301K	–	121
2023 Q2	$301K	Buy	4,704 +15	+0.3%	+$1.01K	0.21%	83
2023 Q1	$325K	Buy	4,689 +1,723	+58%	+$122K	0.23%	72
2022 Q4	$213K	Buy	+2,966	New	+$224K	0.17%	93
2021 Q3	–	Sell	-7,407	Closed	-$495K	–	126
2021 Q2	$495K	Sell	7,407 -558	-7%	-$36.4K	0.42%	49
2021 Q1	$503K	Buy	7,965 +898	+13%	+$55.9K	0.47%	48
2020 Q4	$438K	Buy	+7,067	New	+$435K	0.43%	55

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MRA Advisory Group's BMY Position: Q3 2026 in Review

MRA Advisory Group reduced its Bristol-Myers Squibb (BMY) stake by 76% in Q3 2026, selling an estimated $1.14M and leaving 5,646 shares worth $352K. The position accounts for 0.13% of the portfolio, ranked #99.

MRA Advisory Group first reported a position in BMY in Q4 2020 and has held it in 11 quarters since. The position peaked at $1.36M in Q2 2026. 835 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

MRA Advisory Group held 5,646 shares of Bristol-Myers Squibb worth $352K as of Q3 2026.
MRA Advisory Group sold 18,006 Bristol-Myers Squibb shares in Q3 2026, an estimated $1.14M.
Bristol-Myers Squibb made up 0.13% of MRA Advisory Group's portfolio in Q3 2026, its #99 holding.
MRA Advisory Group first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 11 quarters since.
MRA Advisory Group's Bristol-Myers Squibb position peaked at $1.36M in Q2 2026.
835 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on MRA Advisory Group's 13F filing for Q3 2026, filed 7 Oct 2026.